MedTrace Logo

Role Of Phosphorus And FGF 23 In Patients With Dent Disease

NCT02016235 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2020-03-23

Study results available
· View outcomes & findings →

Summary

Patients with Dent disease have suppressed levels of FGF 23 which contributes to hypercalciuria, kidney stones, nephrocalcinosis and renal failure. Supplementation with phosphorus may reduce hypercalciuria.

Conditions

  • Dent Disease

Interventions

DRUG

Phosphorus Supplement

250 mg po qid

OTHER

Observation

Baseline blood and urine measurements only

Sponsors & Collaborators

Principal Investigators

  • John C Lieske, M.D. · Mayo Clinic

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-09-30
Primary Completion
2019-01-31
Completion
2019-01-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02016235 on ClinicalTrials.gov